| ￥3300 | |
| Z06048-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 35.2 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-45 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of CCL5 hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC. »
CCL5 hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. |
| Synonyms | MuRantes; SIS-delta; Scya5; Ccl5; D17S136E; eoCP; RANTES; SCYA5; SISd; TCP228; CCL5 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
